8-KMaterial AgreementsExhibits & Filings

DEXCOM INC 8-K Report, Material Agreement (Apr 13, 2006)

Filed April 13, 2006For Securities:DXCM

Summary

This Form 8-K filing by DexCom, Inc. (DXCM) on April 13, 2006, primarily reports on two key developments: the entry into a material definitive agreement for the hiring of Steven R. Pacelli as Vice President of Legal Affairs and an update on the compensation structure for non-employee directors. Mr. Pacelli's appointment includes a competitive salary, a signing bonus, and a stock option grant with a four-year vesting schedule. Notably, the agreement outlines change of control provisions, ensuring accelerated vesting of options and severance pay under specific termination scenarios. Additionally, the company's Board of Directors approved an increase in compensation for its non-employee directors, effective April 4, 2006. This includes higher per-meeting attendance fees, increased annual retainers for committee chairpersons, and a significant raise in the annual retainer for the Board Chairperson. The filing also indicates a potential doubling of the annual stock option grant for non-employee directors, subject to stockholder approval. These changes reflect an effort to enhance director compensation and align incentives, particularly in light of potential future corporate events.

Key Highlights

  • 1DexCom, Inc. hired Steven R. Pacelli as Vice President of Legal Affairs via an offer letter agreement dated April 10, 2006.
  • 2Mr. Pacelli will receive an annual salary of $205,000, a $50,000 signing bonus, and an option to purchase 100,000 shares of common stock, vesting over four years.
  • 3The agreement includes change of control provisions for Mr. Pacelli, offering accelerated vesting of stock options and six months salary severance if terminated without cause or constructively terminated.
  • 4The Board of Directors approved increased compensation for non-employee directors, effective April 4, 2006.
  • 5Meeting attendance fees for non-employee directors and committee members increased by $250 per meeting (in-person and telephonic).
  • 6Annual retainers for committee chairpersons and the Board Chairperson were significantly increased, with new retainers established for the nominating/governance and compensation committee chairpersons.
  • 7DexCom is seeking stockholder approval to double the annual stock option grant for non-employee directors from 10,000 to 20,000 shares.

Frequently Asked Questions

Steven R. Pacelli will join DexCom as Vice President of Legal Affairs with an annual salary of $205,000, a $50,000 signing bonus, and an option to purchase 100,000 shares of common stock that vests over four years. The agreement also includes provisions for accelerated vesting of options and severance pay in the event of a change of control or termination without cause.

DexCom's Board of Directors approved increased compensation for non-employee directors. This includes higher per-meeting fees for attending Board and committee meetings, increased annual retainers for committee chairpersons, and a substantial increase in the annual retainer for the Board Chairperson. The company is also proposing to double the annual stock option grant to non-employee directors, pending stockholder approval.

The change of control clauses mean that if DexCom is acquired or undergoes a significant restructuring, and Mr. Pacelli's employment is terminated without cause or he is constructively terminated within 12 months of the event, his unvested stock options will immediately vest, and he would be entitled to six months of salary as severance. This could lead to a dilution of existing shareholder equity or an increase in immediate compensation costs for the company upon such events.

The increase in director compensation and stock option grants is likely intended to attract and retain qualified independent directors, align their interests with shareholders, and recognize the increased responsibilities and time commitment required, especially for committee chairpersons and the Board Chairperson. The proposed increase in stock options is contingent on shareholder approval and aims to further incentivize long-term performance.